Zacks Research Issues Negative Forecast for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at Zacks Research cut their Q1 2025 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a report issued on Tuesday, December 24th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.35 per share for the quarter, down from their previous forecast of $2.42. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.18 per share. Zacks Research also issued estimates for Charles River Laboratories International’s FY2025 earnings at $9.99 EPS, Q1 2026 earnings at $2.75 EPS, Q3 2026 earnings at $2.87 EPS and FY2026 earnings at $11.60 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.72 earnings per share.

Other research analysts have also issued reports about the company. Bank of America dropped their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. UBS Group lifted their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, November 7th. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective for the company. Finally, TD Cowen boosted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and a consensus price target of $214.00.

Charles River Laboratories International Trading Up 0.2 %

Shares of CRL opened at $186.65 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a market cap of $9.54 billion, a PE ratio of 23.36, a PEG ratio of 5.00 and a beta of 1.38. Charles River Laboratories International has a 1 year low of $176.48 and a 1 year high of $275.00. The stock has a 50 day simple moving average of $193.30 and a 200-day simple moving average of $201.43.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its stake in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 40.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company’s stock worth $346,821,000 after purchasing an additional 509,163 shares during the period. Marshall Wace LLP boosted its position in shares of Charles River Laboratories International by 24.6% during the second quarter. Marshall Wace LLP now owns 825,905 shares of the medical research company’s stock worth $170,615,000 after purchasing an additional 163,056 shares in the last quarter. 1832 Asset Management L.P. acquired a new position in shares of Charles River Laboratories International in the 2nd quarter valued at $33,053,000. Finally, Earnest Partners LLC increased its position in shares of Charles River Laboratories International by 12.4% in the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company’s stock valued at $207,507,000 after buying an additional 110,725 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).